Juraj Chudej, Juraj Sokol, Matej Hrnčár, Andrej Rosík, Ján Staško, Peter Kubisz
Cancer patients have approximately 4-times increased risk of venous thromboembolism (VTE) compared with the general
population and this is associated with significant morbidity and mortality. A complex coagulopathy develops in parallel
with malignancy. The pathogenesis of haemostatic alterations in cancer is multifactorial; however, the tumour
tissue capacity to interact with and activate the host haemostatic system plays an important role. Notably, the risk
of VTE varies depending on the type and stage of cancer. Moreover, patients with the metastatic disease have a higher
risk than those with localized tumours. Preventing and treating VTE in cancer patients is challenging. This review summarizes
our current knowledge of VTE and cancer.